Nordic Nanovector - Financial Calendar

OSLO, Norway, Oct.17, 2018 /PRNewswire/ --

FINANCIAL YEAR 2018

Quarterly Report - Q3   06.11.2018 (changed from 21.11.2018)
Quarterly Report - Q4   27.02.2019

FINANCIAL YEAR 2019

Annual General meeting 25.04.2019
Quarterly Report - Q1     23.05.2019
Half-yearly Report          22.08.2019
Quarterly Report - Q3     21.11.2019

The dates are subject to change. The time and location of the presentations will be announced in due time.

This information is published pursuant to the requirements set out in the Continuing obligations.

For further information, please contact:
IR enquiries
Malene Brondberg
VP Investor Relations and Corporate Communications
Cell: +44-7561-431-762
Email: [email protected] 

International Media Enquiries
Mark Swallow/David Dible (Citigate Dewe Rogerson)
Tel: +44-207-638-9571
Email: [email protected]

About Nordic Nanovector
Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company aspires to become a leader in the development of targeted therapies for haematological cancers. Nordic Nanovector's lead clinical-stage candidate is Betalutin®, a novel CD37-targeting antibody-radionuclide-conjugate designed to advance the treatment of non-Hodgkin's lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 20 billion by 2024. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets. Further information can be found at www.nordicnanovector.com

This information was brought to you by Cision http://news.cision.com

http://news.cision.com/nordic-nanovector/r/nordic-nanovector---financial-calendar,c2646221